Chordomas are low-grade
malignancies accounting for 1-4% of primary bone
malignancies. Moreover, local recurrences increase the rate of
metastasis. Our previous study identified the far upstream
element (FUSE)-
binding protein 1 (FUBP1) as a
biomarker and potential therapeutic target for
chordoma. In this study,
lncRNA KRT8P41 was identified as a
lncRNA positively correlated with FUBP1. In
chordoma patients, higher
lncRNA KRT8P41 expression was correlated with a poorer prognosis.
LncRNA KRT8P41 silencing significantly inhibited
chordoma cell proliferation and invasion. miR-193a was negatively correlated with
lncRNA KRT8P41 and FUBP1;
lncRNA KRT8P41 inhibited miR-193a expression, and miR-193a inhibited FUBP1 expression. Furthermore, miR-193a directly bound to
lncRNA KRT8P41 and FUBP1 and
lncRNA KRT8P41 competed with FUBP1 for miR-193a binding and relieved miR-193a-mediated FUBP1 inhibition.
LncRNA KRT8P41 silencing inhibited, whereas miR-193a inhibition promoted
chordoma cell proliferation and invasion; the inhibition of miR-193a attenuated the roles of
lncRNA KRT8P41. Within
chordoma tissues, the expression of miR-193a was decreased, and the expression of FUBP1 increased compared to normal control tissues.
LncRNA KRT8P41 exhibited a positive correlation with FUBP1 and a negative correlation with miR-193a in vivo. Therefore, it was concluded that
lncRNA KRT8P41, miR-193a-3p, and FUBP1 form a
lncRNA-
miRNA-
mRNA axis, modulating the proliferation and invasion of
chordoma cells.